Metropolitan Life Insurance Company (MetLife)’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,950	Closed	-$68.2K	–	2307
2024 Q1	$68.2K	Hold	1,950	–	–	﹤0.01%	1252
2023 Q4	$74.1K	Hold	1,950	–	–	﹤0.01%	1239
2023 Q3	$35.8K	Buy	1,950 +140	+8%	+$2.93K	﹤0.01%	1581
2023 Q2	$47K	Hold	1,810	–	–	﹤0.01%	1458
2023 Q1	$34.2K	Sell	1,810 -272	-13%	-$6.33K	﹤0.01%	1602
2022 Q4	$51.3K	Hold	2,082	–	–	﹤0.01%	1459
2022 Q3	$37.4K	Hold	2,082	–	–	﹤0.01%	1654
2022 Q2	$23.6K	Hold	2,082	–	–	﹤0.01%	1962
2022 Q1	$46.4K	Sell	2,082 -5,704	-73%	-$146K	﹤0.01%	1644
2021 Q4	$340K	Sell	7,786 -1,036	-12%	-$41.4K	﹤0.01%	1669
2021 Q3	$294K	Hold	8,822	–	–	﹤0.01%	1785
2021 Q2	$243K	Buy	+8,822	New	+$184K	﹤0.01%	2010
2021 Q1	–	Sell	-2,769	Closed	-$91.3K	–	2631
2020 Q4	$91.3K	Buy	+2,769	New	+$73.7K	﹤0.01%	2396

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s INBX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,950 shares — an estimated $68.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in INBX in Q4 2020 and held it in 13 quarters. The position peaked at $340K in Q4 2021. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,950 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $68.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
Metropolitan Life Insurance Company (MetLife)'s Inhibrx, Inc. Common Stock position peaked at $340K in Q4 2021.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.